Prime Capital Investment Advisors LLC purchased a new position in shares of Gilead Sciences (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 35,300 shares of the biopharmaceutical company’s stock, valued at approximately $2,529,000. Gilead Sciences makes up 1.9% of Prime Capital Investment Advisors LLC’s investment portfolio, making the stock its 17th biggest position.
A number of other hedge funds have also modified their holdings of the business. BlackRock Inc. lifted its position in shares of Gilead Sciences by 1.5% in the fourth quarter. BlackRock Inc. now owns 103,797,247 shares of the biopharmaceutical company’s stock valued at $7,436,033,000 after acquiring an additional 1,552,359 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 1.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock valued at $2,188,095,000 after acquiring an additional 446,263 shares in the last quarter. Parnassus Investments CA lifted its position in shares of Gilead Sciences by 2.5% in the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after acquiring an additional 464,609 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after acquiring an additional 379,867 shares in the last quarter. Finally, Capital International Investors lifted its position in shares of Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after acquiring an additional 5,205,983 shares in the last quarter. Institutional investors own 78.35% of the company’s stock.
In other news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction on Friday, April 13th. The stock was sold at an average price of $75.56, for a total value of $440,741.48. Following the completion of the sale, the director now directly owns 58,452 shares of the company’s stock, valued at $4,416,633.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total value of $2,087,750.00. Following the completion of the sale, the executive vice president now directly owns 62,738 shares of the company’s stock, valued at $5,239,250.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 308,600 shares of company stock valued at $24,328,226. 1.16% of the stock is owned by insiders.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.70 earnings per share. equities research analysts anticipate that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were paid a dividend of $0.57 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 3.05%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
Several equities analysts have recently weighed in on GILD shares. Credit Suisse Group downgraded Gilead Sciences from an “outperform” rating to a “neutral” rating and raised their target price for the company from $74.35 to $80.00 in a research report on Wednesday, December 20th. Oppenheimer restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, December 21st. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. BMO Capital Markets restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Finally, BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $88.61.
WARNING: This piece was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/17/prime-capital-investment-advisors-llc-takes-position-in-gilead-sciences-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.